Drugs / Ginkgo Biloba Extract
Ginkgo Biloba Extract
also known as
EGb 761 · Tanakan · GBE · Ginkgo biloba leaf extract · ginkgo extract · Cerenin(Ginkgo Biloba Extract) film-coated 40 mg · EGb · GBLE · +4 more
Trials 23
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00032474 | Dec 2001 → May 2005 | type 2 diabetes mellitus | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT04525144 | Oct 2020 → Dec 2025 overdue | cerebrovascular disorder, cognitive impairment with or without cerebellar ataxia | National Neuroscience Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT00824512 | Jun 2008 → Oct 2011 | Friedreich ataxia | Ipsen | Completed | Missed primary |
| Phase 2 | NCT00500500 | Jul 2005 → Apr 2008 | Alzheimer disease | Ipsen | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00029692 | Mar 2002 → Mar 2005 | — | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07709312 | Oct 2026 → Jan 2027 expected | rheumatoid arthritis | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06403787 | May 2022 → Apr 2023 | HIV infectious disease | University of Guadalajara | Completed | No outcome recorded |
| Phase 36 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT06989697 | Jan 2025 → Dec 2026 expected | CGF1, type 2 diabetes mellitus | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT03318276 | Feb 2017 → Oct 2018 | peripheral arterial disease | SK Chemicals Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT01536210 | Dec 2011 → Aug 2012 | mental disorder | Yuyu Pharma, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00276341 | Aug 2003 → Dec 2005 | relapsing-remitting multiple sclerosis | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT00276380 | Feb 2003 → Mar 2009 | ischemic stroke | Ipsen | Completed | Missed primary |
| Phase 3 | NCT00010920 | Sep 1999 → Dec 2004 | dementia | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 46 trials · 1 missed | ||||||
| Phase 4 | NCT07579689 | Jun 2026 → Dec 2028 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Hanyang University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05445895 | Dec 2022 → Oct 2025 | ischemic stroke | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT03483779 | Apr 2018 → Dec 2020 | — | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT01038050 | Oct 2009 → Nov 2010 | coronary atherosclerosis, type 2 diabetes mellitus | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 4 | NCT00042172 | Jun 2002 → Sep 2004 | Alzheimer disease | University of Iowa | Completed | No outcome recorded |
| Phase 4 | NCT00276510 | Feb 2002 → Nov 2009 | cognitive disorder, hippocampal sclerosis of aging | Ipsen | Completed | Missed primary |
| Phase not applicable4 trials | ||||||
| — | NCT06140888 | Mar 2024 → Oct 2026 expected | ischemic stroke | Yi Yang | Not yet recruiting | No outcome recorded |
| — | NCT05398874 | Nov 2021 → Jun 2022 | osteoarthritis, knee | Kufa University | Completed | No outcome recorded |
| — | NCT04492241 | Jul 2021 → Dec 2023 | cognitive impairment with or without cerebellar ataxia | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| — | NCT04121728 | Sep 2019 → May 2024 | CGF1, subjective cognitive decline | Jean-François Démonet | Unknown | No outcome recorded |
| Comparator or background therapy11 trials | ||||||
| Phase 1/2 | NCT00164749 Background | Oct 2004 → Jul 2006 | Alzheimer disease | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 2 | NCT02425436 Comparator | May 2014 → Oct 2015 | fetal growth restriction | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT00814346 Comparator | Oct 2008 → Jul 2012 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Ipsen | Completed | No outcome recorded |
| Phase 2 | NCT01139281 Comparator | Jun 2007 → Jun 2008 | platinum-induced ototoxicity | University of Brasilia | Completed | No outcome recorded |
| Phase 2/3 | NCT06495476 Comparator | Sep 2024 → Oct 2026 expected | cognitive impairment with or without cerebellar ataxia | Beijing Tiantan Hospital | Active not recruiting | No outcome recorded |
| — | NCT06124703 Background | Nov 2023 → Feb 2024 | sensorineural hearing loss disorder, tinnitus | Eye & ENT Hospital of Fudan University | Unknown | No outcome recorded |
| — | NCT07283562 Comparator | Jan 2023 → Oct 2025 | sensorineural hearing loss disorder | The First Hospital of Hebei Medical University | Completed | No outcome recorded |
| — | NCT05591144 Background | Oct 2022 → Jan 2023 | tinnitus | Eye & ENT Hospital of Fudan University | Completed | No outcome recorded |
| — | NCT05258123 Comparator | May 2017 → Jun 2018 | schizophrenia | Beijing HuiLongGuan Hospital | Completed | No outcome recorded |
| — | NCT03425045 Comparator | Mar 2015 → Mar 2018 | tinnitus | University Hospital Ostrava | Completed | No outcome recorded |
| — | NCT01524380 Comparator | Sep 2011 → Jun 2013 | schizophrenia | Beijing HuiLongGuan Hospital | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ginkgo biloba extract | “Patients will receive a light green, oval-shaped, sustained-release film-coated tablet containing a combination of cilostazol (200 mg) and ginkgo biloba extract (160 mg),...” NCT06989697 ↗22“Ginkgo biloba extract not only is a commonly used drug for cardiovascular diseases, but also has a significant effect in reducing blood sugar.” PMID 30405743 ↗ Oct 2018 “We investigated the effects of Ginkgo biloba extract on the symptoms and cognitive functioning in patients with schizophrenia” NCT05258123 ↗ “Both groups received a standard regimen (Dextran-40, Ginkgo Biloba Extract, Mecobalamin, and Yufeng Ningxin Dripping Pills).” NCT07283562 ↗ “Ginkgo biloba extract (EGb 761) has also been reported to improve neurological impairment following AIS.” PMID 39528058 ↗ Nov 2024 |
| Known as | Cerenin(Ginkgo Biloba Extract) film-coated 40 mg | “Cerenin(Ginkgo Biloba Extract) film-coated 40 mg” NCT01038050 ↗ |
| Known as | EGb | “The extract of G. biloba (EGb) is composed of different terpene trilactones, i.e., ginkgolides A, B, C, J and bilobalide, many flavonol glycosides, biflavones and alkylphenols” NCT02425436 ↗ |
| Known as | EGb 761 | “Patients randomised in Arm 3 of the study will receive medication therapy with Ginkgo biloba extract EGb 761 once a day for 6 months.” NCT03425045 ↗13“A standardized Ginkgo biloba extract, EGb 761, may have protective effect against cisplatin-induced ototoxicity in rats.” PMID 17450108 ↗ Sep 2007 “Ginkgo biloba extract (EGb 761) has also been reported to improve neurological impairment following AIS.” PMID 39528058 ↗ Nov 2024 “1) ginseng extract (Ginsana), 2) ginkgo extract (Egb761), 3) both herbs, or 4) matching placebos.” NCT00029692 ↗ “twice per day dose of 120 mg standardised ginkgo biloba extract (EGb761) or matched placebo.” PMID 22959217 ↗ Sep 2012 “EGb 761® 120 mg bid, orally for 12 to 14 weeks” NCT00824512 ↗ “Dietary supplement: Gingko biloba EGb 761” NCT04525144 ↗ “Dietary supplement: Gingko biloba EGb 761” NCT04525144 ↗ |
| Known as | GBE | “This study will also determine whether adding ginkgo biloba extract (GBE) enhances the effects of donepezil.” NCT00042172 ↗1“standardized ginkgo biloba extract (GBE)” NCT00010920 ↗ |
| Known as | GBLE | “Ginkgo biloba leaf extract (GBLE) has an antioxidant action as a free radical scavenger, an improving effect on blood flow or microcirculation, and a stimulating effect on...” NCT07709312 ↗ |
| Known as | Ginkgo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00029692 ↗ |
| Known as | Ginkgo biloba leaf extract | “Ginkgo biloba leaf extract (GBLE) has an antioxidant action as a free radical scavenger, an improving effect on blood flow or microcirculation, and a stimulating effect on...” NCT07709312 ↗1“Patients administrate SID142 (Cilostazol 200mg, Ginkgo biloba leaf extract 160mg) once a day for 12 weeks” NCT03318276 ↗ |
| Known as | ginkgo extract | “YY-162(Ginkgo extract 30mg + Ginseng extract 50mg) 1T/Three times a day(Tid) for 8 weeks, PO medication” NCT01536210 ↗1“1) ginseng extract (Ginsana), 2) ginkgo extract (Egb761), 3) both herbs, or 4) matching placebos.” NCT00029692 ↗ |
| Known as | ginkgo leaf extract | “All patients also received 120 mg/day standardized ginkgo leaf extract.” NCT00164749 ↗ |
| Known as | Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04492241 ↗ |
| Known as | LIFE EXTENSION | “240 mg of LIFE EXTENSION® brand ginkgo biloba extract in 120 mg tablets” NCT06403787 ↗ |
| Known as | Tanakan | “EGb 761® (Tanakan®)” NCT00500500 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “In folk medicine, EGb is used as a vermifuge, to induce labor, for the treatment of bronchitis, chronic rhinitis, chilblains, arthritis and edema” NCT02425436 ↗ |
| Route | Oral | “EGb761® 240 milligrams (mg)/day for 6 months administered orally” NCT00276380 ↗ |